Welcome to our dedicated page for Orchestra BioMed Holdings news (Ticker: OBIO), a resource for investors and traders seeking the latest updates and insights on Orchestra BioMed Holdings stock.
Orchestra BioMed Holdings, Inc. develops biomedical technologies through strategic partnerships with global medical device companies. Its recurring news centers on two late-stage cardiovascular programs: Atrioventricular Interval Modulation Therapy, or AVIM Therapy, for hypertension, and Virtue Sirolimus AngioInfusion Balloon, or Virtue SAB, for atherosclerotic artery disease.
Company updates commonly cover pivotal trial activity, clinical and mechanistic data presentations, FDA Breakthrough Device Designation matters for AVIM Therapy, strategic financing from partners, revenue participation arrangements, and equity-based employee inducement grants. Financial-result releases also discuss cash resources, non-recurring revenue tied to program agreements, and execution of the company's partnership-driven development model.
Orchestra BioMed (Nasdaq: OBIO) announced participation in the Jefferies Global Healthcare Conference. Chairman and CEO David Hochman will join a fireside chat with Jefferies Managing Director Matt Taylor at 9:55 a.m. ET on Thursday, June 4, 2026.
He will also host one-on-one investor meetings on June 3 and 4. The fireside chat will be available via live webcast on the company’s Investor Relations website, open to investors and other interested parties.
Orchestra BioMed (Nasdaq: OBIO) reported Q1 2026 results and clinical progress. Cash, cash equivalents and marketable securities were $94.4 million on March 31, 2026, with a projected cash runway into Q4 2027. Q1 revenue was $0.1 million and net loss attributable to common stockholders was $20.7 million ($0.33/share).
The Company targets completion of BACKBEAT Trial enrollment by Q3 2026, aims for a late-breaking data presentation in Q2 2027, and received a second FDA Breakthrough Device Designation for AVIM Therapy. It also secured $35 million in strategic capital from Medtronic and Ligand and continues to advance the Virtue Trial.
Orchestra BioMed (Nasdaq: OBIO) updated the clinical and regulatory timeline for the global pivotal BACKBEAT Trial of AVIM Therapy in pacemaker-indicated patients with uncontrolled hypertension. Enrollment completion is targeted by the end of Q3 2026, with primary endpoint data planned for presentation in Q2 2027.
The FDA approved a reduction in sample size to 284 evaluable randomized subjects (total enrollment target 316) under the Breakthrough Devices program, while maintaining >90% power to detect at least a 5 mmHg difference in 24-hour ambulatory systolic blood pressure at 3 months. Assuming primary safety and efficacy endpoints are met, Medtronic intends to submit an AVIM Therapy-related marketing application for FDA approval after data analyses and then pursue global approvals.
Orchestra BioMed (Nasdaq: OBIO) received a $15 million tranche from Ligand under a previously announced royalty purchase agreement, completing a scheduled payment and bringing Ligand capital to $40 million to date. The financing grants Ligand a tiered royalty interest in Orchestra BioMed’s future revenue.
Proceeds will fund ongoing randomized pivotal trials for AVIM Therapy and Virtue SAB. Together with a separate $20 million Medtronic investment, Orchestra reported $35 million in fresh strategic capital received on May 1, 2026.
Orchestra BioMed (NASDAQ: OBIO) received a $20 million payment from Medtronic on May 1, 2026, fulfilling a scheduled tranche under their strategic financing agreement and supporting completion of the BACKBEAT Global Pivotal Trial for AVIM Therapy.
Together with a $15 million tranche from Ligand, the company received $35 million in strategic capital; the Medtronic funds were issued as a secured subordinated promissory note convertible to a capped prepaid revenue share tied to FDA approval, with crediting at a low double-digit percentage up to $40 million cumulative.
Orchestra BioMed (Nasdaq: OBIO) announced the FDA granted a second Breakthrough Device Designation for AVIM Therapy on April 30, 2026, expanding indications to patients with uncontrolled hypertension despite medication and a pacemaker indication. The designations cover an addressable U.S. population of over 7.7 million adults and may support NTAP and Transitional Pass-Through reimbursement. Orchestra BioMed is conducting the BACKBEAT Global Pivotal Trial with Medtronic to evaluate AVIM in pacemaker-indicated patients.
Orchestra BioMed (NASDAQ: OBIO) announced presentations at HRS 2026 detailing AVIM Therapy clinical and mechanistic data from MODERATO II and a pressure-volume study. Key findings: immediate mean oSBP reduction of 13.2 mmHg, 97% of patients had >5 mmHg oSBP drop, 6-month mean aSBP 125.2 mmHg, and sustained aSBP reductions through 3.6 years in a sub-cohort. Orchestra is enrolling the BACKBEAT Global Pivotal Trial in collaboration with Medtronic (MDT).
Orchestra BioMed (Nasdaq: OBIO) reported full year 2025 results and a Q4 update highlighting a $106.5 million cash and marketable securities position as of December 31, 2025, plus expected proceeds of $35.0 million from Medtronic and Ligand in Q2 2026 and up to $10.7 million from Haemonetics in 2026.
2025 revenue was $33.5 million (primarily non-recurring related to Terumo arrangements). R&D rose to $58.2 million; net loss narrowed to $52.7 million or ($1.11) per share. Backbeat and Virtue pivotal trials are underway with accelerated BACKBEAT enrollment after Q4 protocol amendments.
Orchestra BioMed (Nasdaq: OBIO) announced two conference presentations at THT (Mar 3, 2026) and CRT (Mar 8, 2026) on AVIM Therapy, a pacemaker-based approach for hypertension, diastolic dysfunction and heart failure.
Presenters will share pilot data showing sustained systolic blood pressure reductions, improved hemodynamics, ventricular remodeling, and ongoing BACKBEAT pivotal study progress.
Orchestra BioMed (Nasdaq: OBIO) said management will attend two institutional investor conferences in March 2026: TD Cowen (March 2-4) and Barclays Global Healthcare (March 10-12). Fireside chats are scheduled for March 3 at 9:50am ET and March 11 at 8:00am ET, with webcasts available live and archived on the company’s investor relations site.